JP2011500718A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500718A5
JP2011500718A5 JP2010530124A JP2010530124A JP2011500718A5 JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5 JP 2010530124 A JP2010530124 A JP 2010530124A JP 2010530124 A JP2010530124 A JP 2010530124A JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5
Authority
JP
Japan
Prior art keywords
mva
antigen
polypeptide
pap
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500718A (ja
JP5669581B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080229 external-priority patent/WO2009052328A1/en
Publication of JP2011500718A publication Critical patent/JP2011500718A/ja
Publication of JP2011500718A5 publication Critical patent/JP2011500718A5/ja
Application granted granted Critical
Publication of JP5669581B2 publication Critical patent/JP5669581B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530124A 2007-10-18 2008-10-16 前立腺癌を処置するためのmvaの使用 Expired - Fee Related JP5669581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96089307P 2007-10-18 2007-10-18
US60/960,893 2007-10-18
PCT/US2008/080229 WO2009052328A1 (en) 2007-10-18 2008-10-16 Use of mva to treat prostate cancer

Publications (3)

Publication Number Publication Date
JP2011500718A JP2011500718A (ja) 2011-01-06
JP2011500718A5 true JP2011500718A5 (enExample) 2011-10-20
JP5669581B2 JP5669581B2 (ja) 2015-02-12

Family

ID=40342626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530124A Expired - Fee Related JP5669581B2 (ja) 2007-10-18 2008-10-16 前立腺癌を処置するためのmvaの使用

Country Status (13)

Country Link
US (2) US7867483B2 (enExample)
EP (1) EP2207564B1 (enExample)
JP (1) JP5669581B2 (enExample)
KR (2) KR101648087B1 (enExample)
CN (1) CN101888853B (enExample)
AU (1) AU2008312444B2 (enExample)
CA (1) CA2702586C (enExample)
DK (1) DK2207564T3 (enExample)
ES (1) ES2608604T3 (enExample)
IL (1) IL204541A (enExample)
NZ (2) NZ584042A (enExample)
RU (1) RU2499606C2 (enExample)
WO (1) WO2009052328A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
AU2008312444B2 (en) * 2007-10-18 2014-02-06 Bavarian Nordic A/S Use of MVA to treat prostate cancer
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
US9575053B2 (en) 2012-03-30 2017-02-21 Kyoto University Urinary biomarker for use in test for prostate cancer
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. キメラ抗原受容体
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
KR20180059922A (ko) * 2015-10-02 2018-06-05 유니버시티 오브 코펜하겐 히스톤 리더 도메인을 차단하는 소분자
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11000578B2 (en) * 2016-02-12 2021-05-11 Madison Vaccines Inc. Treatment of prostate cancer with pap vaccine and PD-1 inhibitor co-therapy
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
JP6964072B2 (ja) * 2016-04-26 2021-11-10 大日本住友製薬株式会社 置換プリン誘導体
EP3463450A4 (en) * 2016-06-03 2020-07-29 Etubics Corporation COMPOSITIONS AND METHODS OF ANTI-TUMOR VACCINATION USING ANTIGENS ASSOCIATED WITH PROSTATE CANCER
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
CN106084027A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP2022536122A (ja) * 2019-06-07 2022-08-12 オレゴン ヘルス アンド サイエンス ユニバーシティ 腫瘍関連抗原特異的t細胞応答
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (en) * 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO116459B1 (ro) * 1991-07-25 2001-02-28 Idec Pharma Corp Compozitie imunogena
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
EP0951541B1 (en) * 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CA2286477A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
DK1137792T3 (da) * 1998-12-09 2007-09-10 Us Gov Health & Human Serv En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
WO2003073828A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
ATE315660T1 (de) * 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
US20070196346A1 (en) * 2003-08-21 2007-08-23 Brown Michael P Poxvirus Vector Encoding Prostate Specific Antigens For Treatment Of Prostate Cancer
BRPI0401465A (pt) 2004-04-20 2006-02-21 Embria Informatica Ltda sistema para administrar interações entre usuários e aplicações de software em um ambiente web
AU2008312444B2 (en) 2007-10-18 2014-02-06 Bavarian Nordic A/S Use of MVA to treat prostate cancer

Similar Documents

Publication Publication Date Title
JP2011500718A5 (enExample)
JP6945301B2 (ja) Hpvおよび関連する疾病のための免疫増強治療ワクチン
Moore et al. Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria
Verardi et al. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication
Gómez et al. Clinical applications of attenuated MVA poxvirus strain
Guse et al. Oncolytic vaccinia virus for the treatment of cancer
EP2958994B1 (en) Vaccine composition
US9707285B2 (en) Vaccination methods
RU2010115220A (ru) Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты
Webster et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
JP2024105526A (ja) 免疫応答を誘導するための組成物
US8734806B2 (en) Immunogenic composition and use thereof
Bubenik et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
JP2018517419A5 (enExample)
JP2014139185A5 (enExample)
Chen et al. Optimisation of prime–boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine
Marcos-Villar et al. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium
RU2019125436A (ru) Новый подход к иммунотерапии, нацеленной на vegfr-2
Iampietro et al. Immunogenicity and cross-reactivity of rhesus adenoviral vectors
Wang et al. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge
Wan et al. As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity-and IL-6-dependent manner
Ren et al. Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination
JP7454320B2 (ja) アジュバントとしての腫瘍溶解性ウイルス
Yang et al. Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity